NeuroVasc Preclinical Services — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

NeuroVasc Preclinical Services is a San Diego-based preclinical CRO founded in 2015, focusing on neuroscience and cardiovascular disease models. The company leverages specialized animal models and technical expertise to conduct efficacy studies for drug developers, with a proven track record in stroke research that has contributed to successful clinical trials. It serves large pharmaceutical and biotech companies, operating as a service provider rather than a therapeutic developer. The company appears to be a private, revenue-generating entity supporting the external R&D pipelines of its clients.

NeuroscienceCardiovascular

Technology Platform

Specialized portfolio of preclinical animal models for central nervous system (CNS) and vascular diseases, with deep expertise in stroke models and associated efficacy pharmacology study design and analysis.

Opportunities

Growing demand for specialized preclinical CRO services in the large and underserved neuroscience and cardiovascular drug development markets.

The company's proven track record in generating clinically translatable data, as evidenced by its work leading to a Phase II stroke trial, provides a strong competitive marketing advantage to attract major pharmaceutical clients.

Risk Factors

High competition from both large full-service CROs and other niche players.

Revenue is dependent on a cyclical biopharma R&D spending and project-based contracts, creating potential volatility.

Operational risks include maintaining stringent study quality, animal welfare compliance, and data integrity to protect its reputation.

Competitive Landscape

NeuroVasc competes in the preclinical CRO market, facing broad competition from large, publicly traded players like Charles River Laboratories and Labcorp's preclinical segment, which offer global scale and a full suite of services. Its differentiation lies in its specialized neurovascular focus, competing against other boutique CROs that offer deep expertise in specific disease areas. Success depends on maintaining a reputation for superior model fidelity and data quality.

More companies in United States →